![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RB-ADSC is an ex vivo expanded, autologous adipose-derived stem cell therapy, which is currently being evauated for the treatment of mild-to-moderate Alzheimer’s disease.
Lead Product(s): RB-ADSC
Therapeutic Area: Neurology Product Name: RB-ADSC
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024